Hôpital Avicenne, Assistance Publique, Hôpitaux de Paris and Paris 13 University, Bobigny, France.
Leuk Res. 2010 Nov;34(11):1410-6. doi: 10.1016/j.leukres.2010.05.021. Epub 2010 Jul 6.
Azacitidine is currently the only drug to have shown a significant survival benefit over conventional care regimens in patients with International Prognostic Scoring System (IPSS) intermediate-2 (Int-2) and high-risk myelodysplastic syndromes (MDS), establishing it as an important new treatment for these individuals. However, several aspects of the practical use of azacitidine remain uncertain. This manuscript outlines recommendations discussed by a panel of experts, providing a practical guide for physicians to ensure optimal management of Int-2 and high-risk patients receiving azacitidine.
阿扎胞苷是目前唯一在国际预后评分系统（IPSS）中-2（Int-2）和高危骨髓增生异常综合征（MDS）患者中显示出明显生存获益的药物，优于传统治疗方案，为这些患者提供了一种重要的新治疗方法。然而，阿扎胞苷的实际应用的几个方面仍然不确定。本文概述了专家组讨论的建议，为医生提供了一个实用指南，以确保接受阿扎胞苷治疗的 Int-2 和高危患者得到最佳管理。
